REFERENCES

References used to support the information on this website, by section:
  1. Goldenberg MM, et al. Multiple sclerosis review. Pharmacy and Therapeutics 2012;37(3):175–184.
  2. Gilmour H, et al. Multiple sclerosis: Prevalence and impact. Statistics Canada. Available at: www.statcan.gc.ca. Release date: January 2018.
  3. MS Society of Canada. Symptoms. Available at: https://mssociety.ca/about-ms/symptoms. Accessed May 2020.
  4. Cascella M, et al. Features, evaluation and treatment coronavirus (COVID-19). Available at: https://www.ncbi.nlm.nih.gov/books/NBK554776/. Accessed June 2020.
  5. MS International Federation. The coronavirus and MS – updated global advice. Last updated: 18 June, 2020. Available at: https://www.msif.org/news/2020/02/10/the-coronavirus-and-ms-what-you-need-to-know/. Accessed June 2020.
  6. World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Available at: https://covid19.who.int/. Accessed June 2020.
  7. Johns Hopkins Medicine. What is coronavirus? Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus. Accessed June 2020.
  8. World Health Organization. Coronavirus overview. Available at: https://www.who.int/health-topics/coronavirus#tab=tab_1. Accessed May 2020.
  9. Centers for Disease Control and Prevention. People who are at higher risk for severe illness. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html. Accessed June 2020.
  10. World Health Organization. Coronavirus symptoms. Available at: https://www.who.int/health-topics/coronavirus#tab=tab_3. Accessed May 2020.
  11. World Health Organization. Q&A on coronaviruses (COVID-19). Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses. Accessed June 2020.
  12. World Health Organization. Coronavirus disease (COVID-19) advice for the public. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public. Accessed May 2020.
  13. MS Society of Canada. What you need to know about coronavirus. Available at: https://mssociety.ca/resources/what-you-need-to-know-about-coronavirus. Accessed May 2020.
  14. National MS Society. Multiple Sclerosis and coronavirus. Available at:  https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus. Accessed June 2020.
  15. COViMS. COVID-19 Infections in MS & Related Diseases. Available at: https://www.covims.org/. Accessed June 2020.
  16. Macaron G and Ontaneda D. Diagnosis and management of progressive multiple sclerosis. Biomedicines 2019;7:56.
  17. Government of Canada. Coronavirus disease (COVID-19): prevention and risks. Available at: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks.html. Accessed June 2020.
  18. Government of Canada. How to isolate at home when you may have COVID-19. Available at: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/covid-19-how-to-isolate-at-home.html. Accessed June 2020.
  19. National MS Society. Multiple Sclerosis FAQs. https://www.nationalmssociety.org/What-is-MS/MS-FAQ-s. Accessed September 2020.
  20. Harvard Health Publishing. Hugs heartfelt in more ways than one. Available at: https://www.health.harvard.edu/newsletter_article/In_brief_Hugs_heartfelt_in_more_ways_than_one. Accessed July 2020.
  1. Giovannoni G, et al. Brain health: Time matters in multiple sclerosis. Mult Scler Relat Disord 2016;9(Suppl 1):S5–48.
  2. Cree BAC, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 2019;85:653–66.
  3. National MS Society. Research News. Available at: https://www.nationalmssociety.org/Research/Research-News-Progress. Accessed July 2020.
  4. Azevedo FAC, et al. Equal number of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. Journal of Comparative Neurology 2009. 513:532–541.
  5. NASA. Universe 101: The Milky Way. Available at: http://map.gsfc.nasa.gov/universe/rel_milkyway.html. Accessed July 2020.
  6. Eroglu C and Barres BA. Regulation of synaptic connectivity by glia. Nature 2010;468:223–231. 
  7. Lodish H, et al. Molecular Biology 4th ed. New York: W. H. Freeman; Section 21.2. Online book available at http://www.ncbi.nlm.nih.gov/books/NBK21668/. Accessed July 2020.
  8. National Health and Nutrition Examination Survey (NHANES) 1999–2002. Centers for Disease Control and Prevention. In: Mean Body Weight, Height, and Body Mass Index United States 1960-2002.
  9. MS International Federation. What is MS? Available at: https://www.msif.org/about-ms/what-is-ms/. Accessed November 2020.
  10. Dunn SE, et al. Sex-based differences in multiple sclerosis (MS): Part II: Rising incidence of multiple sclerosis in women and the vulnerability of men to progression of this disease. Curr Top Behav Neurosci 2015;26:57–86.
  11. Brown JW, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019;321(2):175–187.
  12. Word Health Organization. 2020. Healthy diet. Available at: https://www.who.int/news-room/fact-sheets/detail/healthy-diet. Accessed March 2020.
  13. Kappos L, et al. Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the phase III OPERA I and OPERA II studies. Poster presented at: the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 10–12 October 2018; Berlin, Germany. Poster P547.
  14. Trojano M, et al. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurol Sci 2003;24(Suppl. 5):S268–S270.
  15. National MS Society. Secondary progressive multiple sclerosis. Available at:  https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS. Accessed May 2020.
  16. Tedeholm H, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler 2013;19(6):765–774.
  17. MS Society of Canada. Primary Progressive MS. Available at: https://mssociety.ca/managing-ms/living-with-ms/progressive-ms. Accessed August 2020.
  18. Kutzelnigg A, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128(11):2705–2712.
  19. National MS Society. Medications. Available at: https://stage.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-The-MS-Disease-Modifying-Medications.pdf. Accessed September 2020.
  20. MS Society of Canada. Symptoms. Available at: https://mssociety.ca/about-ms/symptoms. Accessed August 2020.
  21. Lizarraga AA, et al. Multiple sclerosis in 2019: predicting progression. Lancet Neurol 2020;19(1):12–14.
  22. Wiendl W and Meuth SG. Pharmacological approaches to delaying disability progression in patients with multiple sclerosis. Drugs 2015;75:947–77.
  23. Cinar BP and Yorgun YG. What we learned from the history of multiple sclerosis measurement: expanded disability status scale. Noro Psikiyatr Ars 2018;55(Suppl 1):S69–75.
  24. Stankiewicz JM, et al. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2020;7:e636.
  25. Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics 2013;10:97–105.
  26. Brownlee WJ, et al. Diagnosis of multiple sclerosis: progress and challenges. Lancet 2017;389:1336–46.
  27. Schulz D, et al. Cognition in the early stages of multiple sclerosis. J Neurol 2006;253:1002–10.
  28. White CP, et al. Invisible and visible symptoms of multiple sclerosis: Which are more predictive of health distress? J Neurosci Nurs 2008;40:85–95.
  29. Kasser SL, et al. Symptom variability, affect and physical activity in ambulatory persons with multiple sclerosis: Understanding patterns and time-bound relationships. Disabil Health J 2017;10:207–13.
  30. Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handb Clin Neurol 2014;122:269–90.
  31. Murphy KL, et al. Multiple sclerosis: Perspectives in treatment and pathogenesis, Chapter 4. 2017.
  32. Braley TJ and Chervin RD. Fatigue in multiple sclerosis: Mechanisms, evaluation, and treatment. Sleep 2010;33:1061–7.
  33. Beiske AG, et al. Pain and sensory complaints in multiple sclerosis. Eur J Neurol 2004;11:479–82.
  34. Davis SL, et al. Thermoregulatory dysfunction in multiple sclerosis. Handb Clin Neurol 2018;157:701–14.
  35. National MS Society. Dizziness and vertigo. Available at: https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms/Dizziness-and-Vertigo. Accessed July 2020.
  36. de Silva RN, et al. Diagnosis and management of progressive ataxia in adults. Pract Neurol 2019;19:196–207.
  37. Hugos CL and Cameron MH. Assessment and measurement of spasticity in MS: State of the evidence. Curr Neurol Neurosci Rep 2019;19:79.
  38. Balci PB. Spasticity measurement. Arch Neuropsychiatry 2018;55:(Suppl 1):S49−53.
  39. Oreja-Guevara C, et al. Cognitive dysfunctions and assessments in multiple sclerosis. Frontier Neurol 2019;10:(581)1–9.
  40. Feenaughty L, et al. Speech and pause characteristics in multiple sclerosis: A preliminary stuy of speakers with high and low neuropsychological test performance. Clin Linguist Phon 2013;27:134–51.
  41. Merson RM and Rolnick MI. Speech-language pathology and dysphagia in multiple sclerosis. Phys Med Rehabil Clin N Am 1998;9:631–41.
  42. De Pauw A, et al. Dysphagia in multiple sclerosis. Clin Neurol Neurosurg 2002;104:345–51.
  43. National MS Society. Pain & Itching. Available at: https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms/Pain. Accessed July 2020.
  44. Koch M, et al. Tremor in multiple sclerosis. J Neurol 2007;254:133–45.
  45. Schmidt EZ, et al. Sexuality in multiple sclerosis. J Neural Transm 2005;112;1201–11.
  46. Fletcher SG, et al. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol 2009;6:96–107.
  47. Sa MJ. Psychological aspects of multiple sclerosis. Clin Neurol Neurosurg 2008;110;868–77.
  48. Löffler LAK, et al. Emotional dysfunctions in neurodegenerative diseases. J Comp Neurol 2016;524:1727–43.
  49. Mahadeva A, et al. Urinary tract infections in multiple sclerosis: under-diagnosed and under-treated? A clinical audit at a large university hospital. Am J Clin Exp Immunol 2014;3:57–67.
  50. Hodge BH. The use of symptom diaries in outpatient care. Fam Pract Manag 2013;20:24–28.
  51. National MS Society. Working with your doctor. Available at: http://www.nationalmssociety.org/getmedia/41d32d7f-6da1-4919-93d5-187dd9d08a33/Volume6. Accessed July 2020.
  52. National MS Society. Cognitive Changes. Available at: https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms/Cognitive-Changes. Accessed September 2020.
  53. Ben-Zacharia A, et al. Impact of shared decision making on disease-modifying drug adherence multiple sclerosis. Int J MS Care 2018; 20(6): 287–297.
  54. Wendrich, K et al. Toward digital self-monitoring of multiple sclerosis. Int J MS Care 2019; 21(6): 282–291.
  55. MS Society of Canada. Spasticity, Mobility Problems and Multiple Sclerosis. Available at: https://mssociety.ca/qc/Documentation/spasticity_web.pdf. Accessed August 2020.
  56. Smith PEM. If it’s not epilepsy. J Neurol Neurosurg Psychiatry 2001;70(Suppl II):ii9-ii14.
  57. Epilepsy.com. Clonic seizures. Available at: https://www.epilepsy.com/learn/types-seizures/clonic-seizures. Accessed July 2020.
  58. MS in focus. Spasticity in MS. Issue 12. Available at: https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Documents/MS-in-focus-11-Spasticity-English.pdf. Accessed August 2020.
  59. NCBI Bookshelf. Characteristics and management of major symptoms – MS. Available at: https://www.ncbi.nlm.nih.gov/books/NBK222388/. Accessed July 2020.
  60. MS News Today. Need to know: How to manage MS leg spasticity. Available at: https://multiplesclerosisnewstoday.com/2019/01/10/leg-spasticity-manage-ms-need-to-know/. Accessed July 2020.
  61. Healthline. Open swim: Multiple sclerosis water therapy. Available at: https://www.healthline.com/health/multiple-water-therapy. Accessed July 2020.
  62. MedlinePlus. Caring for muscle spasticity or spasms Available at: https://medlineplus.gov/ency/patientinstructions/000063.htm. Accessed July 2020.
  63. Healthline. Everything you need to know about bladder spasms. Available at: https://www.healthline.com/health/bladder-spasms. Accessed July 2020.
  64. MS Society of Canada. Bladder dysfunction in MS. Available at: https://mssociety.ca/en/pdf/bladder-dysfunction.pdf. Accessed August 2020.
  65. Multiple Sclerosis Association of America. Bladder dysfunction. Available at: https://mymsaa.org/ms-information/symptoms/bladder-dysfunction/. Accessed July 2020.
  66. MS in focus. Bladder and bowel. Available at:https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Documents/MS-in-focus-24-Bladder-and-bowel-issues-English.pdf. Accessed August 2020.
  67. Namey M, et al. Elimination dysfunction in multiple sclerosis. Int J MS Care 2012;14(Suppl I):1–26. 
  68. Preziozi G, et al. Neurogenic bowel dysfunction in patients with multiple sclerosis: prevalence, impact, and management strategies. Degener Neurol Neuromuscul Dis 2018:79–90.
  69. Jeyarajah S and Purkayastha S. Proctalgia fugax. CMAJ Practice 2013; 2013, 185(5) (appendix).
  70. Hertz R, et al. Multiple sclerosis presenting with facial twitching (myokymia and hemifacial spasms). Case Rep Neurol Med 2017;2017:7180560.
  71. Collazo IM and Tobin WO. Facial myokymia and hemifacial spasm in multiple sclerosis. The Neurologist 2018;23:1–6.
  72. Johns Hopkins. Blepharspasm. Available at: https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/vestibular/conditions/blepharospasm.html#:~:text=Conditions%20We%20Treat%3A%20Blepharospasm&text=It%20is%20due%20to%20dystonia,lower%20face%20on%20that%20side. Accessed November 2020.
  73. Induruwa I, et al. Fatigue in multiple sclerosis – a brief review. J Neurol Sci 2012;323:9–15.
  74. NCBI. Characteristics and Management of Major Symptoms. Available at: https://www.ncbi.nlm.nih.gov/books/NBK222388/. Accessed July 2020.
  75. MS Society of Canada. Fatigue info sheet. Available at: https://mssociety.ca/library/document/rJfL1dpR3wsaAEvX284B5ITCnVQxy67S/original.pdf. Accessed August 2020.
  76. MS in focus. Fatigue and MS. Available at: https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Documents/MS-in-focus-19-Fatigue-English.pdf. Accessed August 2020.
  77. Gümüş, H. Fatigue can be objectively measured in multiple sclerosis. Arch Neuropsychiatry 2018;55(Suppl 1):S76−79.
  78. Joy JE, et al. Institute of Medicine. Multiple sclerosis: Current status and strategies for the future. Washington, DC: The National Academies Press. 2001;177–240.
  79. WebMD. Fight MS fatigue. Available at: https://www.webmd.com/multiple-sclerosis/ms-fatigue. Accessed July 2020.
  80. Irish LA, et al. The role of sleep hygiene in promoting public health: A review of empirical evidence. Sleep Med Rev 2016;22:23–36.
  81. Simpson R, et al. Mindfulness based interventions in multiple sclerosis – a systemic review. BMC Neurol 2014;14:15.
  82. MS International Federation. Fatigue: an invisible symptom of MS. Available at: http://www.msif.org/wp-content/uploads/2020/04/MS-FATIGUE-BOOKLET-WEB.pdf. Accessed July 2020.
  83. Mulligan H, et al. Perceived impact of a self-management program for fatigue in multiple sclerosis. Int J MS Care 2016;18:27–32.
  84. Tur C, et al. Fatigue management in multiple sclerosis. Curr Treat Options Neurol 2016;18:26.
  85. WebMD. The benefits of cognitive therapy for MS. Available at: https://www.webmd.com/multiple-sclerosis/cognitive-therapy-benefits. Accessed August 2020.
  86. van Kessel K, et al. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med 2008;70:205–13.
  87. Shaygannejad V, et al. Comparison of the effect of aspiring and amantadine for the treatment of fatigue in multiple sclerosis: A randomized, blinded, crossover study. Neurol Res 2012;34:854–8.
  88. UpToDate. Approach to the adult patient with fatigue. Available at: https://www.uptodate.com/contents/approach-to-the-adult-patient-with-fatigue. Accessed November 2020.
  89. CCOHS. Fatigue. Available at: https://www.ccohs.ca/oshanswers/psychosocial/fatigue.html#:~:text=Acute%20fatigue%20results%20from%20short,is%20not%20relieved%20by%20rest. Accessed November 2020.
  90. MS International Federation. What is MS fatigue? Available at: http://www.msif.org/wp-content/uploads/2020/04/MS-FATIGUE-BOOKLET-WEB.pdf. Accessed November 2020.
  91. MS Society of Canada. Cognition and MS. Available at: https://mssociety.ca/library/document/LrvdiAzUK01SbsCcafFt938eQhNP2IJ7/original.pdf. Accessed August 2020.
  92. MS Society of Canada. Mood & cognition in MS: What You Can Do. Available at: https://www.mstrust.org.uk/life-ms/wellbeing/thinking-and-memory-problems https://mssociety.ca/uploads/files/mood-and-congition-in-ms-EN.pdf. Accessed August 2020.
  93. MS Society of Canada. Stress and multiple sclerosis. Available at: https://mssociety.ca/library/document/bl4nKmqMU28riIFkpvGzjdCVP9s3huRJ/original.pdf. Accessed August 2020.
  94. Thomas PW, et al. Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev 2006;1:CD004431.
  95. Sumowski JF, et al. Cognition in multiple sclerosis. Neurology 2018;90:278–88.
  96. Perez-Martin MY, et al. Efficacy of short cognitive training program in patients with multiple sclerosis. Neuropsych Dis Treat 2017;13:245–52.
  97. Jonkman LE, et al. Gray matter correlates of cognitive performance differ between relapsing-remitting and primary-progressive multiple sclerosis. PLoS One 2015;10:e0129380.
  98. Cleveland Clinic. Multiple sclerosis (MS): Impaired cognition. Available at: https://my.clevelandclinic.org/health/diseases/14455-multiple-sclerosis-ms-impaired-cognition. Accessed July 2020.
  99. Lynch SG, et al. The association between cognitive impairment and physical disability in multiple sclerosis. Mult Scler 2005;11:469–76.
  100. VeryWellHealth. An overview of cognitive impairment in multiple sclerosis. Available at: https://www.verywellhealth.com/cognitive-impairment-in-ms-2440794. Accessed July 2020.
  101. DeLuca J, et al. Treatment and management of cognitive dysfunction in patients with multiple sclerosis. Nat Rev Neurol 2020;16,319–32.
  102. Healthline. Cog fog: How to deal with this frequent MS symptom. Available at:  https://www.healthline.com/health/multiple-sclerosis/cog-fog-science-and-tips#1. Accessed July 2020.
  103. Gal RL, et al. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev 2015;8:CD001430.
  104. Healthline. Coping with vision changes. Available at:  https://www.healthline.com/health/multiple-sclerosis/vision-disturbances#coping. Accessed August 2020.
  105. Healthline. Uhthoff’s phenomenon: Understanding overheating. Available at: https://www.healthline.com/health/multiple-sclerosis/uhthoffs-phenomenon. Accessed August 2020.
  106. National MS Society. Vision problems in multiple sclerosis. Available at: https://www.nationalmssociety.org/nationalmssociety/media/msnationalfiles/brochures/brochure-vision-problems.pdf. Accessed July 2020.
  107. MS Society of Canada. Programs and services: Disabled driver testing/retesting. Available at: https://mssociety.ca/support-services/programs-and-services/1153/disabled-driver-testingretesting. Accessed August 2020.
  108. Canadian Ophthalmological Society. Multiple sclerosis. Available at: https://www.cos-sco.ca/vision-health-information/conditions-disorders-treatments/neuroophthalmology/multiple-sclerosis/. Accessed August 2020.
  109. Cleveland Clinic. 4 Early warning signs of MS you shouldn’t ignore. Available at: https://health.clevelandclinic.org/4-early-signs-of-ms-you-shouldnt-ignore/. [accessed August 2020].
  110. Graves J and Balcer LJ. Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol 2010;4:1409–22.
  111. Mayo Clinic. Multiple sclerosis. Available at: https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20350269?p=1. Accessed July 2020.
  112. Adriana ID, et al. Management of diplopia. Romanian J Ophthalmol 2017;61:166–70.
  113. Jasse L, et al. Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability. Mult Scler 2013;19:1618–26.
  114. Serra A, et al. Eye movement abnormalities in multiple sclerosis: pathogenesis, modeling, and treatment. Front Neurol 2018;9:31.
  115. Niestroy A, et al. Neuro-ophthalmologic aspects of multiple sclerosis: Using eye movements as a clinical and experimental tool. Clin Ophthalmol 2007;1:267–72.
  116. Medscape. What is Nystagmus in Multiple Sclerosis? Available at: https://www.medscape.com/answers/1214270-166040/what-is-nystagmus-in-multiple-sclerosis-ms. Accessed July 2020.
  117. Hobson F and Rowe FJ. Management of nystagmus by surgery and botulinum toxin options: a review. Br Orthopt J 2009;6:28–33.
  118. Pula JH, et al. Diagnosis and treatment of visual disturbances in multiple sclerosis. Int J MS Care 2010;12:106–13.
  119. Healthline. Available at: https://www.healthline.com/health/kaleidoscope-vision Accessed July 2020.
  120. Kister I, et al. Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course. J Headache Pain 2010;11:417–25.
  121. New Life Outlook. How common Is kaleidoscopic vision in people with MS? Available at: https://ms.newlifeoutlook.com/kaleidoscope-vision-multiple-sclerosis/ Accessed July 2020.
  122. Summit Medical Group. Vision, blind spot (scotoma). https://www.summitmedicalgroup.com/library/adult_health/oph_scotoma/ [accessed July 2020].
  123. Multiple Sclerosis Association of America. Visual Disorders. Available at:  https://mymsaa.org/ms-information/symptoms/visual-disorders/. Accessed August 2020.
  124. All About Vision. Ocular and visual migraines: What’s the difference? Available at: https://www.allaboutvision.com/en-ca/conditions/ocular-migraine/. Accessed August 2020.
  125. van Dongen RM and Haan J. Symptoms related to the visual system in migraine [version 1; peer review: 2 approved] F1000Res 2019;8:1219.
  126. Medical News Today. How does MS affect the eyes? Available at: https://www.medicalnewstoday.com/articles/325451. Accessed July 2020.
  127. Moss HE. Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown. Eye Brain 2017;9:13–21.
  128. Panginikkod S, et al. Uhthoff phenomenon. NCIB Bookshelf. Available at: https://www.ncbi.nlm.nih.gov/books/NBK470244/. Accessed October 2020.
  129.  
  130. National MS Society. Vision problems. Available at: https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms/Vision-Problems#:~:text=In%20MS%2C%20diplopia%2C%20or%20double,muscles%20that%20allow%20eye%20movement. Accessed October 2020.
  131. Nystagmus Network. Treating nystagmus. Available at: https://nystagmusnetwork.org/what-is-nystagmus/treating-nystagmus/. Accessed October 2020.
  132. Cameron MH and Nilsagard Y. Balance, gait, and falls in multiple sclerosis. Handb Clin Neurol 2018;159:237–50.
  133. Ashizawa T and Guangbin X. Ataxia. Continuum (Minneap Minn) 2016;22:1208–26.
  134. Wilkins A. Cerebellar dysfunction in multiple sclerosis. Front Neurol 2017;28;8:312.
  135. Mayo Clinic. Ataxia. Available at: https://www.mayoclinic.org/diseases-conditions/ataxia/symptoms-causes/syc-20355652?p=1. Accessed August 2020.
  136. Mount Sinai Hospital. MS Symptoms. Available at: https://www.mountsinai.on.ca/care/ebffrc/ms-symptoms. Accessed August 2020.
  137. WebMD. MS Drugs Compared. Available at: https://www.webmd.com/multiple-sclerosis/ms-drugs-comparison. Accessed August 2020.
  138. Vestibular Disorders Association. Labyrinthitis and Vestibular Neuritis. Available at: https://vestibular.org/labyrinthitis-and-vestibular-neuritis. Accessed August 2020.
  139. MS Society of Canada. Exercise and Physical Activity. https://mssociety.ca/hot-topics/exercise-and-physical-activity 1/12. Accessed August 2020.
  140. Hebert JR, et al. Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upgright postural control: A randomized controlled trial. Phys Ther 2011;91:1166–83.
  141. Hebert JR, et al. Efficacy of balance and eye-movement and eye-movement exercises for person with multiple sclerosis. Neurology 2018;27;90:e797–807.
  142. Carling A, et al. Balance exercise facilitates everyday life for people with multiple sclerosis: A qualitative study. Physiother Res Int 2018;23:e1728.
  143. Carling A, et al. CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled piloty study. Mult Scler 2017;23:1394–404.
  144. National MS Society. Yoga and MS. Available at: https://www.nationalmssociety.org/Living-Well-With-MS/Diet-Exercise-Healthy-Behaviors/Exercise/Yoga. Accessed July 2020.
  145. MedFitNetwork. Why do yoga if you have multiple sclerosis? Available at: https://medfitnetwork.org/public/all-mfn/yoga-multiple-sclerosis/. Accessed July 2020.
  146. Cohen ET, et al. Feasibility and impact of an 8-week integrative yoga program in people with moderate multiple sclerosis-related disability. Int J MS Care 2017;19:30–39.
  147. Brichetto G, et al. The effect of Nintendo® Wii® on balance in people with multiple sclerosis: a pilot randomized control study. Mult Scler J 2013;19:1219–21.
  148. Prosperini L, et al. Home-based balance training using the Wii balance board: A randomized, crossover pilot study in multiple sclerosis. Neurorehabil Neural Repair 2013;27:516–25.
  149. Ozkul C, et al. Effect of immersive virtual reality on balance, mobility, and fatigue in patients with multiple sclerosis: A single-blinded randomized controlled trial. Eur J Integr Med 2020;35:101092.
  150. Maggio MG, et al. Virtual reality in multiple sclerosis rehabilitation: A review on cognitive and motor outcomes. J Clin Neurosci 2019;65:106–11.
  151. MS Society of Canada. Rehabilitation. Available at: https://mssociety.ca/managing-ms/living-with-ms/ms-care/rehabilitation-in-ms. Accessed August 2020.
  152. Frohman EM, et al. Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques. Mult Scler J 2003;9:250–55.
  153. Johns Hopkins Medicine. Benign paroxysmal positional vertigo (BPPV). Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/benign-paroxysmal-positional-vertigo-bppv. Accessed July 2020.
  154. Verywell Health. An overview of vertigo in MS. Available at: https://www.verywellhealth.com/vertigo-in-multiple-sclerosis-2440805 [accessed July 2020].
  155. Merck Manuals. Dizziness & vertigo. Available at: https://www.merckmanuals.com/en-ca/home/ear,-nose,-and-throat-disorders/symptoms-of-ear-disorders/dizziness-and-vertigo. Accessed August 2020.
  156. NCBI. Characteristics and Management of Major Symptoms. Available at: https://www.ncbi.nlm.nih.gov/books/NBK222388/. Accessed July 2020.
  157. Truini A, et al. A mechanism-based classification of pain in multiple sclerosis. J Neurol 2013;260:351–67.
  158. Zadeh AR, et al. Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2. Int J Physiol Pathophysiol Pharmacol 2019;11:105–14.
  159. NIH. Peripheral neuropathy fact sheet. Available at: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Peripheral-Neuropathy-Fact-Sheet. Accessed July 2020.
  160. National MS Society. Pain & itching. Available at: https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms/Pain. Accessed August 2020.
  161. Foley PL, et al. Prevalence and natural history of pain in adults with multiple sclerosis: Systemic review and meta-analysis. Pain 2013;154:632–42.
  162. Gebhardt M, et al. Headache in the first manifestation of multiple sclerosis – prospective, multicenter study. Brain Behav 2017;7:e00852.
  163. Zagon IS and McLaughlin PJ. Multiple sclerosis. Perspectives in treatment and pathogenesis. Brisbane: Codon Publications; 2017.
  164. Spine Health. Cold and heat therapy for sciatica. Available at: https://www.spine-health.com/conditions/sciatica/cold-and-heat-therapy-sciatica. Accessed July 2020.
  165. Monro R, et al. Disc extrusions and bulges in nonspecific low back pain and sciatica: Exploratory randomised controlled trial comparing yoga therapy and normal medical treatment. J Back Musculoskelet Rehabil 2015;28:383–92.
  166. VeryWellHealth. An Overview of headaches in MS. Available at: https://www.verywellhealth.com/headaches-in-multiple-sclerosis-2440798. Accessed July 2020.
  167. MedicalNewsToday. What is Lhermitte’s sign?. Available at: https://www.medicalnewstoday.com/articles/323889#causes-of-lhermittes-sign. Accessed August 2020.
  168. Stefano GD, et al. Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain 2019;20:20.
  169. Shayestehazar M, et al. A survey of severity and distribution of musculoskeletal pain in multiple sclerosis patients; a cross-sectional study. Arch Bone Jt Surg 2015;3:114–18.
  170. O’Connor AB, et al. Pain associated with multiple sclerosis: Systemic review and proposed classification. Pain 2008;137:96–111.
  171. VeryWellHealth. The MS hug. Available at: https://www.verywellhealth.com/multiple-sclerosis-hug-2440802. Accessed July 2020.
  172. MS International Federation. MS pain. Available at: https://www.msif.org/about-ms/symptoms-of-ms/pain/. Accessed July 2020.
  173. Luwimi IA, et al. Pathophysiology of Paresthesia. Paresthesia. InTech; 2012.
  174. VeryWellHealth. What does MS pain feel like? Available at: https://www.verywellhealth.com/overview-of-pain-as-a-symptom-of-multiple-sclerosis-2440808. Accessed July 2020.
  175. National MS Society. Acupuncture. Available at: https://www.nationalmssociety.org/Treating-MS/Complementary-Alternative-Medicines/Acupuncture. Accessed August 2020.
  176. National MS Society. Massage and bodywork. Available at: https://www.nationalmssociety.org/Treating-MS/Complementary-Alternative-Medicines/Massage-and-Body-Work. Accessed August 2020.
  177. Adamec I, et al. Erythromelalgia as a manifestation of autonomic nervous ystem involvement in multiple sclerosis. Mult Scler Relat Disord 2016;8:1–3.
  178. Halabchi F, et al. Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendations. BMC Neurol 2017;17:185.
  179. WebMD. When should I use heat or ice for pain? Available at: https://www.webmd.com/pain-management/when-use-heat-ice#1. Accessed July 2020.
  180. Galey T, et al. Sensory abnormalities in MS: Patient descriptions of “macrosomic illusions”. Int J MS Care 2004;4:144–7.
  181. Medical News Today. MS hug: What you Need to Know. Available at: https://www.medicalnewstoday.com/articles/320146. Accessed July 2020.
  182. Very Well Health. The Multiple Sclerosis ‘Hug’. Available at: https://www.verywellhealth.com/multiple-sclerosis-hug-2440802. Accessed July 2020.
  183. National MS Society. Pain & Itching. Available at: https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms/Pain. Accessed August 2020.
  184. Ju ZY, et al. Acupuncture for neuropathic pain in adults (review). Cochrane Database Syst Rev 2017(12): CD012057.
  185. Miller L, et al. The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler J 2007;13: 527–33.
  186. National MS Society. Acupuncture. Available at: https://www.nationalmssociety.org/Treating-MS/Complementary-Alternative-Medicines/Acupuncture. Accessed August 2020.
  187. Zagon IS and McLaughlin PJ. Multiple sclerosis. Perspectives in treatment and pathogenesis. Brisbane: Codon Publications; 2017.
  188. WebMD. Steroids for MS Flares. Available at: https://www.webmd.com/multiple-sclerosis/treating-iv-steroids. Accessed October 2020.
  189. Powell DJH, et al. Tracking daily fatigue fluctuations in multiple sclerosis: ecological momentary assessment provides unique insights. J Behav Med 2017;40:772–83.
  190. Schumacher GA, et al. Problems of experimental trails of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965;122:552–68.
  191. Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 2015;5:e00362.
  192. Lovblad KO, et al. MR imaging in multiple sclerosis: Review and recommendations for current practice. AJNR Am J Neuroradiol 2010;31:983–89.
  193. Chiappa KH. Pattern-shift visual, brainstem auditory and short-latency somatosensory evoked potentials in multiple sclerosis. Neurology 1980;30:110–23.
  194. Engelborghs S, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst) 2017;8:111–126.
  195. Merck Manuals. Multiple sclerosis (MS). Available at: https://www.merckmanuals.com/en-ca/home/brain-spinal-cord-and-nerve-disorders/multiple-sclerosis-ms-and-related-disorders/multiple-sclerosis-ms#. Accessed July 2020.
  196. Scolding N. The differential diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;71:ii9–15.
  197. Kale N. Optic neuritis as an early sign of multiple sclerosis. Eye Brain 2016;8:195–202.
  198. The Canadian Association of Optometrists. Comprehensive eye exams: Vital for more than just your vision. Available at: https://opto.ca/health-library/comprehensive-eye-exams-vital-for-more-than-just-your-vision. Accessed July 2020.
  199. Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302.
  200. Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–73.
  201. Medina LD, et al. Patient-reported outcomes in multiple sclerosis: Validation of the quality of life in neurological disorders (Neuro-QoL™) short forms. Mult Scler J Exp Transl Clin 2019:5:1–11.
  202. Learmonth YC, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 2013;13:37.
  203. Institute for Quality and Efficiency in Health Care (IQWiG). What happens during a neurological examination? Available at: https://www.ncbi.nlm.nih.gov/books/NBK348940/. Accessed June 2020.
  204. Neurological Advisor. In multiple sclerosis, hand strength may indicate disease status. Available at: https://www.neurologyadvisor.com/conference-highlights/cmsc-2017/in-multiple-sclerosis-hand-strength-may-indicate-disease-status/. Accessed June 2020.
  205. Healthline. What’s the connection between MS and optic neuritis? Available at: https://www.healthline.com/health/multiple-sclerosis/optic-neuritis  [accessed June 2020]
  206. MS Society of Canada. Takeaways from the Canadian MS Working Group 2020 Treatment Optimization Recommendations. Available at: https://mssociety.ca/takeaways-from-the-canadian-ms-working-group-2020-treatment-optimization-recommendations. Accessed July 2020.
  207. Healthline. Why an MRI is Used to Diagnose Multiple Sclerosis. Available at: https://www.healthline.com/health/multiple-sclerosis/images-brain-mri. Accessed July 2020.
  208. Ontario’s MRI and CT Expert Panel. Ontario Best Practice Guidelines for Managing the Flow of Patients Requiring an MRI or CT Examination. Available at: https://collections.ola.org/mon/23006/292809.pdf. Accessed July 2020.
  209. MS Society of Canada. Diagnosis. Available at: https://mssociety.ca/about-ms/diagnosing-ms. Accessed June 2020.
  210. Palace J. Making the diagnosis of multiples sclerosis. J Neurol Neurosurg Psychiatry 2001;71(Suppl II):ii3–8.
  211. Johns Hopkins Medicine. Sensory evoked potentials studies. Available at: https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/sensory-evoked-potentials-studies. Accessed June 2020.
  212. WebMD. Multiple sclerosis and evoked potential tests. Available at: https://www.webmd.com/multiple-sclerosis/evoked-potential-tests. Accessed July 2020.
  213. Pokryszko-Dragan A. Assessment of visual and auditory evoked potentials in multiple sclerosis with and without fatigue. Neurol Sci 2015; 36:235–242.
  214. Sunnybrook health sciences centre. Frequently asked questions: EEG & EP. Available at: https://sunnybrook.ca/content/?page=bsp-eeg-esp-faq. Accessed July 2020.
  215. Sakka L, et al. Anatomy and physiology of cerebrospinal fluid. Eur Ann Otorhinolaryngol Head Neck Dis 2011;128:309–16.
  216. Mayo Clinic. Lumbar puncture (spinal tap). Available at: https://www.mayoclinic.org/tests-procedures/lumbar-puncture/about/pac-20394631?p=1. Accessed July 2020.
  1. Paty DW, et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:662–7.
  2. Giovannoni G, et al. Brain health: Time matters in multiple sclerosis. Mult Scler Relat Disord 2016;9(Suppl 1):S5–48.
  3. Stankiewicz JM, et al. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2020;7:e636.
  4. MS Society of Canada. Treatments. Available at: https://mssociety.ca/managing-ms/treatments/medications. Accessed May 2020.
  5. MS Society of Canada. Symptom management. Available at: https://mssociety.ca/managing-ms/treatments/medications/symptom-management. Accessed August 2020.
  6. MS Society of Canada. Rehabilitation. Available at: https://mssociety.ca/managing-ms/living-with-ms/ms-care/rehabilitation-in-ms [accessed August 2020]
  7. MS Society of Canada. Disease-modifying therapies. Available at: https://mssociety.ca/managing-ms/treatments/medications/disease-modifying-therapies-dmts. Accessed May 2020.
  8. National MS Society. Managing relapses. Available at: https://www.nationalmssociety.org/Treating-MS/Managing-Relapses. Accessed October 2020.
  9. Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics 2013;10:97–105.
  10. Burks JS, et al. Rehabilitation challenges in multiple sclerosis. Ann Indian Acad Neurol 2009;12:296–306.
  11. Murphy R, et al. Neuropsychiatric syndromes of multiple sclerosis. J Neurol Neurosurg Psych 2017;88:697–708.
  12. Ben-Zacharia A, et al. Impact of shared decision making on disease-modifying drug adherence multiple sclerosis. Int J MS Care 2018; 20(6):287–297.
  13. National MS Society. Adherence. Available at: https://www.nationalmssociety.org/Treating-MS/Medications/Adherence. Accessed May 2020.
  14. Cohen BA, et al. Therapy optimization in multiple sclerosis: A cohort study of therapy adherence and risk of relapse. Mult Scler Relat Disord 2015;4:75–82.
  15. Hupperts R, et al. The STAR study: A real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis. Clin Ther 2014;36:1946–57.
  16. MS Society of Canada. Working with your MS healthcare team. Available at: https://mssociety.ca/managing-ms/living-with-ms/ms-care/working-with-your-ms-healthcare-team. Accessed August 2020.
  1. National MS Society. Research & news progress. Available at: https://www.nationalmssociety.org/Research/Research-News-Progress. Accessed August 2020.
  2. MS Society of Canada. Wellness & lifestyle. Available at: https://mssociety.ca/managing-ms/living-with-ms/wellness-and-lifestyle. Accessed July 2020.
  3. MS Society of Canada. Exercise and physical activity. Available at: https://mssociety.ca/hot-topics/exercise-and-physical-activity?query=mental%20health. Accessed July 2020.
  4. Canadian Society for Exercise Physiology (CSEP). Canadian physical activity guidelines. Available at: https://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf. Accessed August 2020.
  5. Government of Canada. Physical activity and your health. Available at: https://www.canada.ca/en/public-health/services/being-active/physical-activity-your-health.html. Accessed August 2020.
  6. Canadian Physiotherapy Association (CPA). 2012 Description of physiotherapy in Canada. Available at: https://physiotherapy.ca/sites/default/files/site_documents/dopen-en.pdf. Accessed August 2020.
  7. National MS Society. Rehabilitation. Available at: https://www.nationalmssociety.org/Treating-MS/Rehabilitation#section-1. Accessed August 2020.
  8. MS Society of Canada. Rehabilitation. Available at: https://mssociety.ca/managing-ms/living-with-ms/ms-care/rehabilitation-in-ms. Accessed August 2020.
  9. National MS Society. Heat and temperature sensitivity. Available at: https://www.nationalmssociety.org/Living-Well-With-MS/Diet-Exercise-Healthy-Behaviors/Heat-Temperature-Sensitivity. Accessed August 2020.
  10. MS Society of Canada. Symptoms. Available at: https://mssociety.ca/about-ms/symptoms. Accessed August 2020.
  11. National MS Society. Building better balance. Available at: https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Resources_Support/Effect-of-MS-on-Balance.pdf. Accessed August 2020.
  12. National MS Society. A resource for healthcare professionals: physical therapy in multiple sclerosis. Available at: http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Clinical_Bulletin_Physical-Therapy-in-MS-Rehabilitation.pdf. Accessed August 2020.
  13. Carling A, et al. Balance exercise facilitates everyday life for people with multiple sclerosis: A qualitative study. Physiother Res Int 2018;23:e1728.
  14. Carling A, et al. CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled piloty study. Mult Scler J 2017;23:1394–404.
  15. Hebert JR, et al. Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upgright postural control: A randomized controlled trial.  Neurology 2018;90:e797–807.
  16. Hebert JR, et al. Efficacy of balance and eye-movement and eye-movement exercises for person with multiple sclerosis.  Phys Ther 2011;91:1166–83.
  17. MS Society of Canada. Physical Activity Guide for People With MS. MS Society of Canada Web site. Available at: https://mssociety.ca/library/document/qR3n1N5M2hYdsUx4TOrIzAm8lQ0XDZVp/original.pdf. Accessed August 2020.
  18. Carling A, et al. CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled piloty study.  Mult Scler J 2017 (Appendix);23:1394–404.
  19. Nilsagård YE, et al. Balance exercise program reduced falls in people with multiple sclerosis: A single-group, pretest-posttest trial. Arch Phys Med Rehabil 2014;95:2428–34.
  20. The Mayo Clinic. Fitness. Available at: https://www.mayoclinic.org/healthy-lifestyle/fitness/in-depth/strength-training/art-20046670?p=1. Accessed August 2020.
  21. MS Society of Canada. Physical Activity Guide for People with MS. Available at: https://mssociety.ca/library/document/qR3n1N5M2hYdsUx4TOrIzAm8lQ0XDZVp/original.pdf. Accessed August 2020.
  22. National MS Society. Yoga and MS. Available at: https://www.nationalmssociety.org/Living-Well-With-MS/Diet-Exercise-Healthy-Behaviors/Exercise/Yoga. Accessed August 2020.
  23. Government of Canada. Canada’s Food Guide: Section 1. Available at: https://food-guide.canada.ca/en/guidelines/section-1-foundation-for-healthy-eating/. Accessed August 2020.
  24. MS Society of Canada. Diet. https://mssociety.ca/hot-topics/diet?gclid=EAIaIQobChMIpYfS-66H6wIVMxh9Ch2mXwzYEAAYASAAEgK7p_D_BwE. Accessed August 2020.
  25. Government of Canada. Canada’s Food Guide: Section 2. Available at: https://food-guide.canada.ca/en/guidelines/section-2-foods-and-beverages-that-undermine-healthy-eating/. Accessed March 2020.
  26. Tryfonos C, et al. Dietary supplements on controlling multiple sclerosis symptoms and relapses: Current clinical evidence and future perspectives. Medicines 2019;6:95.
  27. Sand IK, et al. The role of diet in multiple sclerosis: Mechanistic connections and current evidence. Curr Nutr Rep 2018;7:150–60.
  28. Evans E, et al. An overview of the current state of evidence for the role of specific diets in multiple sclerosis. Mult Scler Relat Disord 2019;36:101393.
  29. Chenard CA, et al. Nutrient composition comparison between the low saturated fat Swank diet for multiple sclerosis and healthy U.S.-style eating pattern. Nutrients 2019;11:616.
  30. Wahls T, et al. Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized controlled trial. Trials 2018;19:309.
  31. Yadav V, et al. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial. Mult Scler Relat Disord 2016;9:80–90.
  32. Sand IK, et al. Randomized-controlled trial of a modified Mediterranean dietary program for multiple sclerosis: A pilot study. Mult Scler Relat Disord 2019;36:101403.
  33. WebMD. Do multiple sclerosis and alcohol mix (page 1)? Available at: https://www.webmd.com/multiple-sclerosis/features/do-ms-alcohol-mix#1. Accessed March 2020.
  34. WebMD. Do multiple sclerosis and alcohol mix (page 2)? Available at: https://www.webmd.com/multiple-sclerosis/features/do-ms-alcohol-mix#2. Accessed March 2020.
  35. Alcohol.org. Alcohol and slurred speech. Available at: https://www.alcohol.org/effects/slurred-speech/. Accessed June 2020.
  36. McKay KA, et al. Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. Mult Scler J 2016;22:685–93.
  37. Murphy R, et al. Neuropsychiatric syndromes of multiple sclerosis. J Neurol Neurosurg Psychiatry 2017;88:697–708.
  38. Quesnel S and Feinstein A. Multiple sclerosis and alcohol: A study of problem drinking. Mult Scler 2004;10:197–201.
  39. MS Society of Canada. Employers guide. Available at: https://mssociety.ca/en/pdf/EmployersGuide.pdf. Accessed August 2020.
  40. Leslie M, et al. Patterns in workplace accommodations for people with multiple sclerosis to overcome cognitive and other disease-related limitations. Neuro Rehabilitation 2015;37:425–36.
  41. Government of Canada. Employment equity. Available at: https://www.canada.ca/en/employment-social-development/programs/employment-equity.html. Accessed June 2020.
  42. Kasser SL, et al. Symptom variability, affect and physical activity in ambulatory persons with multiple sclerosis: Understanding patterns and time-bound relationships. Disabil Health J 2017;10:207–13.
  43. Powell DJH, et al. Tracking daily fatigue fluctuations in multiple sclerosis: ecological momentary assessment provides unique insights. J Behav Med 2017;40:772–83.
  44. WebMD. Can you still work with MS? Available at: https://www.webmd.com/multiple-sclerosis/ms-and-work. Accessed June 2020.
  45. Indeed.com. 10 Questions to ask yourself before applying for a job. Available at: https://www.indeed.com/career-advice/finding-a-job/questions-to-ask-before-applying-for-a-job. Accessed June 2020.
  46. National MS Society. Successful job interviewing. Momentum Magazine 2008. Available at:  https://www.nationalmssociety.org/Programs-and-Services/Resources/Successful-Job-Interviewing-(-pdf)?page=1&orderby=3&order=asc. Accessed June 2020.
  47. MS Society of Canada. Talking about MS with employers. Available at: https://mssociety.ca/managing-ms/newly-diagnosed/talking-about-ms/employers#:~:text=Talking%20About%20MS%20With%20Employers,are%20asking%20for%20job%20accommodation. Accessed June 2020.
  48. Schneiderman N, et al. Annu Rev Clin Psychol 2005;1:607–28.
  49. National MS Society. Taming stress in multiple sclerosis. Available at: https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-Taming-Stress.pdf. Accessed May 2020.
  50. MS Society of Canada. Rehabilitation. Available at: https://mssociety.ca/managing-ms/living-with-ms/ms-care/rehabilitation-in-ms. Accessed August 2020.
  51. American Psychological Association. Coping with stress at work. Available at: http://www.apa.org/helpcenter/work-stress. Accessed May 2020.
  52. WHSC. Work Stress. Available at: https://www.whsc.on.ca/Files/What-s-New/Work-Stress_WHSC-Resource-Line.aspx. Accessed June 2020.
  53. National MS Society. Fatigue. Available at: https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms/Fatigue. Accessed May 2020.
  54. Multiple Sclerosis Association of America. Fatigue. Available at: https://mymsaa.org/ms-information/symptoms/fatigue/. Accessed May 2020.
  55. MS Society of Canada. Talking about MS with employers. Available at: https://mssociety.ca/managing-ms/newly-diagnosed/talking-about-ms/employers. Accessed April 2020.
  56. National MS Society. Whom should I tell? Available at: https://www.nationalmssociety.org/Living-Well-With-MS/Work-and-Home/Employment/Disclosure-Decisions/Whom-Should-I-tell. Accessed May 2020.
  57. MS Society of Canada. Employers guide. Available at: https://mssociety.ca/en/pdf/EmployersGuide.pdf. Accessed August 2020.
  58. MS Society of Canada. Fatigue info sheet. Available at: https://mssociety.ca/library/document/rJfL1dpR3wsaAEvX284B5ITCnVQxy67S/original.pdf. Accessed August 2020.
  59. Nilsagard Y and Bostrom B. Informing the children when a parent is diagnosed as having multiple sclerosis. Int J MS Care 2015;17:42–8.
  60. Petrikis P, et al. Quality of life and emotional strain in caregivers of patients with multiple sclerosis. J Clin Neurol. 2019;15:77–83.
  61. Foley FW and Beier M. Assessment and treatment of sexual dysfunction in multiple sclerosis. Available at: https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Clinical_Bulletin_Sexual-Dysfunction-in-MS.pdf. Accessed May 2020.
  62. MS in focus: Special focus on the family. Issue 3. Available at: https://www.msif.org/wp-content/uploads/2014/09/MS-in-focus-3-Family-English.pdf. Accessed June 2020.
  63. Young CA, et al. Sexual functioning in multiple sclerosis: Relationships with depression, fatigue and physical function. Mult Scler 2017;23:1268–75.
  64. MS International Federation. Family life. Available at: https://www.msif.org/living-with-ms/family-life/. Accessed May 2020.
  65. National MS Society. Relationships. Available at: https://www.nationalmssociety.org/Living-Well-With-MS/Relationships. Accessed May 2020.
  66. Foley FW, et al. Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis. Mult Scler 2001;7:417–21.
  67. Schmidt EZ, et al. Sexuality in multiple sclerosis. J Neural Transm 2005;112:1201–11.
  68. Domingo S, et al. Factors associated with sexual dysfunction in individuals with multiple sclerosis. Int J MS Care 2018;20:191–7.
  69. Balsamo R, et al. Increased risk of erectile dysfunction in men with multiple sclerosis: an Italian cross-sectional study. Cent European J Urol 2017;70:289–95.
  70. Döring A, et al. Exercise in multiple sclerosis – an integral component of disease management. EPMA J 2011;3:2.
  71. Sa MJ. Psychological aspects of multiple sclerosis. Clin Neurol Neurosurg 2008;110:868–77.
  72. Koch T, et al. Constructions of sexuality for women living with multiple sclerosis. J Adv Nurs 2002;39:137–45.
  73. Dobson R, et al. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol 2019;19:106–14.
  74. MS Society of Canada. Pregnancy. Available at: https://mssociety.ca/managing-ms/womens-health/pregnancy. Accessed June 2020.
  75. Michel L, et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry 2012;83:796–802.
  76. Alirezaei S, Ozgoli G, et al. Evaluation of factors associated with sexual function in infertile women. Int J Fertil Steril 2018;12:125–9.
  77. John Hopkins Medicine. Multiple sclerosis and pregnancy. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/multiple-sclerosis-ms/multiple-sclerosis-and-pregnancy. Accessed May 2020.
  78. Bove R and Gilmore W. Hormones and MS: Risk factors, biomarkers, and therapeutic targets. Mult Scler J 2018;24:17–21.
  79. Confavreux C, et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998;339:285–91.
  80. Giovannoni G, et al. MS Brain Health: Time matters in multiple sclerosis. Available at: http://msbrainhealth.org/perch/resources/time-matters-in-ms-report-may16.pdf. Accessed June 2020.
  81. MS International Federation. Childhood MS a guide for parents. Available at: https://www.msif.org/wp-content/uploads/2016/06/Childhood-MS-A-Guide-for-Parents-email-version.pdf. Accessed June 2020.
  82. National MS Society. Pediatric MS. Available at: https://www.nationalmssociety.org/What-is-MS/Who-Gets-MS/Pediatric-MS. Accessed May 2020.
  83. Silva P. Canadian study of MS-prone family proves that in rare cases, multiple sclerosis is inherited. Available at: https://multiplesclerosisnewstoday.com/2017/04/21/ms-study-canadian-family-mutations-proves-multiple-sclerosis-inhe/. Accessed June 2020.
  84. Westerlind H. Modest familial risks for multiple sclerosis: A registry-based study of the population of Sweden. Brain 2014;137:770–8.
  85. US National Library of Medicine. Multiple sclerosis. Available at:https://ghr.nlm.nih.gov/condition/multiple-sclerosis#inheritance. Accessed June 2020.
  86. National MS Society. What causes MS. Available at: https://www.nationalmssociety.org/What-is-MS/What-Causes-MS#section-4. Accessed June 2020.
  87. Great Ormond Street Hospital. Multiple sclerosis: information for families. Available at: https://www.gosh.nhs.uk/conditions-and-treatments/conditions-we-treat/multiple-sclerosis. Accessed June 2020.
  88. Murphy R, et al. Neuropsychiatric syndromes of multiple sclerosis. J Neurol Neurosurg Psychiatry 2017;88:697–708.
  89. Johns Hopkins Medicine. Multiple Sclerosis and mental health: 3 common challenges. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/multiple-sclerosis-ms/multiple-sclerosis-and-mental-health-3-common-challenges. Accessed July 2020.
  90. Marrie RA, et al. Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. BMC Res Notes 2017;10:619–625.
  91. Chwastiak LA and Ehde DM. Psychiatric issues in multiple sclerosis. Psychiatr Clin North Am 2007;30:803–817.
  92. Healthline. Advancing MS: Coping with depression, stress, and anger. Available at: https://www.healthline.com/health/multiple-sclerosis/depression-stress-anger. Accessed July 2020.
  93. Mayo Clinic. Managing depression in MS. Available at: https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/expert-answers/managing-depression-in-ms/faq-20111498. Accessed July 2020.
  94. Mayo Clinic. Managing anxiety in MS: What works? Available at: https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/expert-answers/managing-anxiety-in-ms/faq-20112504. Accessed July 2020.
  95. WebMD. The benefits of cognitive therapy for MS. Available at: https://www.webmd.com/multiple-sclerosis/cognitive-therapy-benefits. Accessed July 2020.
  96. Hind D, et al. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: A systemic review and meta-analysis. BMC Psychiatry 2014;14:5.
  97. Kiropoulos LA, et al. A pilot randomized controlled trial of a tailored cognitive behvaioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis. BMC Psychiatry 2016;16:435.
  98. MS Society of Canada. Programs and services – community mental health agencies. Available at: https://mssociety.ca/support-services/programs-and-services/953/mental-health. Accessed July 2020.
  99. MS Society of Canada. Mental health helpline. https://mssociety.ca/support-services/programs-and-services/1150/mental-health-helpline. Accessed July 2020.
  100. CAMH. Anxiety medication. Available at: https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/anti-anxiety-medications-benzodiazepines. Accessed December 2020.
  101. CAMH. Anxiety disorders. Available at: https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/anxiety-disorders. Accessed July 2020.
  102. Anxiety Canada. Social anxiety disorder. Available at: https://www.anxietycanada.com/disorders/social-anxiety-disorder/. Accessed July 2020.
  103. Butler E, et al. A systemic review of anxiety amongst people with multiple sclerosis. Mult Scler Relat Disord 2016;10:145–68.
  104. Anxiety Canada. Understanding panic attacks. Available at: https://www.anxietycanada.com/articles/understanding-panic-attacks. Accessed July 2020.
  105. CAMH. Anti-anxiety medications. Available at: https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/anti-anxiety-medications-benzodiazepines. Accessed July 2020.
  106. Henry A, et al. Anxiety and depression in patients with multiple sclerosis: The mediating effects of perceived social support. Mult Scler Relat Disord 2019;27:46–51.
  107. Freeman D, et al. The effects of improving sleep on mental health (OASIS): A randomised controlled trial with mediation analysis. Lancet Psychiatry 2017;4:749–58.
  108. Magnavita N and Garbarino S. Sleep, health and wellness at work: A scoping review. Int J Environ Res Public Health 2017;14:1347.
  109. MS Society Canada. Programs and services. https://mssociety.ca/support-services/programs-and-services/1150/mental-health-helpline. Accessed May 2020.
  110. Freeman J, et al. “A non-person to the rest of the world”: Experiences of social isolation amongst severely impaired people with multiple sclerosis. Disabil Rehabil 2019;18:1–9.
  111. MS Society of Canada. Peer Support Groups. Available at: https://mssociety.ca/support-services/programs-and-services/support-and-self-help-groups. Accessed July 2020.
  112. MS Society of Canada. Friendly Visiting. https://mssociety.ca/support-services/friendly-visiting. Accessed July 2020.
  113. Fasczewski KS, et al. I ride for MS: The impact of bike MS participation on motivation for physical activity in individuals with multiple sclerosis. Disabil Health J 2020;13:100853.
  114. Shavazi MA, et al. Online social support for patients with multiple sclerosis: A thematic analysis of messages posted to a virtual support community. Int J Community Based Nurs Midwifery 2016;4:188–98.
  115. MS Society of Canada. Information and resources. Available at: https://mssociety.ca/support-services/caregivers/information-and-resources. Accessed July 2020.
  116. MS Society of Canada. MS knowledge network. Available at: https://mssociety.ca/support-services/ms-knowledge-network. Accessed July 2020.
  117. MS Society of Canada. Find services in your area. Available at: https://mssociety.ca/support-services/programs-and-services. Accessed July 2020.
  118. MS Society Canada. Support services. Available at: https://mssociety.ca/support-services. Accessed May 2020.
Roche Logo
Privacy policy Terms and conditions Cookie policy Site map References
© 2021 F. Hoffmann-La Roche Ltd. 5248E21v
This website contains materials intended only for residents of Canada and may contain product details or information not available or valid outside of Canada. We accept no responsibility for users outside of Canada accessing portions of this website which may be invalid or non-compliant with the laws, regulations or standards of the user’s home country. This website is neither intended nor designed to record or report adverse event information. If you have a suspected side effect or problem to report regarding one of our products, please email mississauga.canada_medinfo@roche.com or call Canada Roche Drug Safety at 1 - 888 - 762 - 4388 You can also report adverse events relating to any product to Health Canada directly by going to the Canada Vigilance Program website at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html
Ad Standards checkmark